CA-OPENGATE-CAPITAL
OpenGate Capital , a global private equity firm, announced today that its portfolio company, EverZinc, a European specialty zinc chemical business, has acquired G.H. Chemicals Ltd., and Microzinc Inc., collectively referred to as “GHC”, a Canadian manufacturer and exporter of French Process zinc oxide products. Terms of the transaction were not disclosed.
GHC was established in 1974 and is based in Saint Hyacinthe, Quebec. Through its manufacturing facility, GHC produces four grades of French Process zinc oxide used for pharmaceutical and food products, as well as fertilizer and feed grades, and various grades for rubber compounding. The business was acquired from Mr. Stephan Tabah and Mr. Philippe Bailet. GHC has a seasoned team of professionals and a highly trained employee base of 58 people serving a customer base of industrial, pharmaceutical and agriculture customers.
“The acquisition of GHC is a transformational investment for EverZinc that provides product and market expansion through world class facilities in Quebec,” said Andrew Nikou, OpenGate Capital’s Founder and CEO. “OpenGate’s strategy is to build both organic and inorganic growth for the businesses in which we invest. Earlier this year OpenGate launched OGx, a new digital optimization capability, to grow EverZinc and now GHC. Through the investment in GHC, and the OGx platform, we are confident that EverZinc’s global product offering will better serve its customers.”
Vincent Dujardin, CEO of EverZinc, stated, “We are excited to welcome GHC into the EverZinc portfolio and look forward to working together to leverage our respective products, processes and better serve our customer bases.”
Fabien Marcantetti, Managing Director in OpenGate’s Paris office, who led the transaction, added, “We are incredibly proud of completing this acquisition as the business provides many accretive aspects to EverZinc. Stephan and Philippe have driven advancements in the business and we are looking forward to working with them in the many months ahead.”
Julien Lagreze, Partner at OpenGate Capital, also commented, “The GHC transaction represents OpenGate’s second add-on acquisition which we believe further strengthens the investments acquired in our first institutional fund. I am very pleased that this is another milestone achieved within OpenGate’s investment strategy.”
OpenGate has completed two add-on investments including G.H. Chemicals and Aico S.P.A, an Italian manufacturer of home heating products, an add-on to Jøtul Group, acquired in March of 2018.
About OpenGate Capital
OpenGate Capital is a global private equity firm specializing in the acquisition and operation of businesses to create new value through operational improvements, innovation and growth. Established in 2005, OpenGate Capital is headquartered in Los Angeles, California with a European office in Paris, France. OpenGate’s professionals possess the critical skills needed to acquire, transition, operate, build and scale successful businesses. To date, OpenGate Capital, through its legacy and fund investments, has executed more than 30 acquisitions including corporate carve-outs, management buy-outs, special situations and transactions with private sellers across North America and Europe. To learn more about OpenGate, please visit www.opengatecapital.com .
About EverZinc
EverZinc is a global leader in the production of zinc materials with four product lines: fine zinc powders, zinc oxide, ultra-fine zinc powder and zinc powders for batteries. Industrial operations are in Belgium, the Netherlands, Norway, China and Malaysia. Close to 175,000 tons of materials are produced from 8 facilities to serve our global customer base. EverZinc products are used in a wide variety of applications including anti-corrosion paints, tires, pharma/chemicals, ceramics and glass, sunscreen, alkaline batteries and other products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190125005009/en/
Contact:
OpenGate Media Contacts Alanna Chaffin Email: achaffin@opengatecapital.com Telephone: +1 (310) 432-7000
Mike Sitrick Sitrick & Company Email: Mike_Sitrick@sitrick.com Telephone: (310) 788-2850
OpenGate Business Development Contact Joshua Adams Email: jadams@opengatecapital.com Telephone: +1 (310) 432-7000
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom